secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001193125-25-157390
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bezuclastinib SUMMIT trial beats all primary/secondary endpoints; NDA submission by end 2025
--------------------------------------------------------------------------------

- SUMMIT trial met primary endpoint: mean TSS reduction of 24.3 vs 15.4 placebo (p=0.0002); 8.91-point placebo-adjusted improvement.
- 87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% placebo (p<0.0001).
- NDA submission to FDA expected by end of 2025; plan to present full data at medical meeting.
- Raised ~$230M gross via offering of 22.2M shares at $9 (plus underwriter option fully exercised).
- Cash balance ~$237M as of June 30, 2025; access to up to $350M via debt facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525157390/0001193125-25-157390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525157390/d92808d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer